3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
37
Lymphoma, Non-Hodgkin
34
Lymphoma, Follicular
32
Lymphoma, Large B-Cell, Diffuse
30
Lymphoma, Mantle-Cell
20
Lymphoma, B-Cell, Marginal Zone
13
Leukemia, Lymphocytic, Chronic, B-Cell
13
Waldenstrom Macroglobulinemia
9
Lymphoma, Large-Cell, Immunoblastic
9
Burkitt Lymphoma
9
Lymphoma, B-Cell
6
Lymphoma, Large-Cell, Anaplastic
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
2
Leukemia
2
Recurrence
1
Orbital lymphoma
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, AIDS-Related
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoproliferative Disorders
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts